KRTCAP2 (keratinocyte associated protein 2) functions as a critical component of the STT3A-containing oligosaccharyl transferase complex (OST-A), which catalyzes the initial step in protein N-glycosylation by transferring glycans from dolichol-pyrophosphate to asparagine residues in nascent polypeptides 12. Within this complex, KRTCAP2 serves as an adapter that anchors the OST-A complex to the Sec61 complex at the endoplasmic reticulum translocon, facilitating cotranslational N-glycosylation 2. The protein may specifically participate in N-glycosylation of amyloid-beta precursor protein (APP) and can modulate gamma-secretase cleavage by enhancing PSEN1 endoproteolysis 3. KRTCAP2 has emerged as a significant biomarker across multiple diseases. In hepatocellular carcinoma, elevated KRTCAP2 expression correlates with poor prognosis and reduced immune infiltration 4. The gene shows prognostic relevance in pancreatic cancer, where it associates with hypoxic conditions and worse outcomes 5. Additionally, KRTCAP2 has been identified as a potential therapeutic target in various contexts, including gout susceptibility 6 and male infertility, where it may indicate testicular spermatogenic capacity 7. These findings highlight KRTCAP2's dual role in essential cellular glycosylation processes and disease pathogenesis.